Astrazeneca Plc ADR (NQ: AZN )
69.37 +0.17 (+0.25%) Streaming Delayed Price Updated: 3:25 PM EDT, Mar 31, 2023 Add to My Watchlist
Headline News about Astrazeneca Plc ADR
COVID Remains A Global Threat – NanoViricides Set To Begin Clinical Trials For Pan-Coronavirus Drug To Help Defeat COVID Once And For All
Today 9:29 EDT
Effective treatments for COVID-19 remain very few and very limited in their capabilities, even after three years. As a result, there are still high rates of hospitalizations and COVID remains many...
AstraZeneca Unusual Options Activity
March 27, 2023
P/E Ratio Insights for AstraZeneca
March 16, 2023
A Look Into AstraZeneca's Debt
March 15, 2023
GSK's Chief Scientist Says R&D Focus More On Infectious Disease, HIV Amid Patent Expiration, Dwindling Sales
March 15, 2023
GSK Plc's (NYSE: GSK) top scientist, Tony Wood, who took the helm of R&D last August, says the R&D department is now delivering results. Wood said he is de-emphasizing R&D in oncology and that the R&D...
Week In Review: Keymed/Lepu Sign $1.2 Billion Deal Out-Licensing Claudin 18.2 ADC To AstraZeneca
February 25, 2023
Keymed Bio and Lepu Biopharma out-licensed global rights for their antibody drug conjugate to AstraZeneca in a deal that includes $63 million upfront. Meanwhile, the $937 million agreement between...
Via Talk Markets
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following